QIAGEN Strengthens European Molecular Diagnostics Team
Lynda A. Merrill to lead the Company's dedicated sales force as VP Molecular Diagnostics Europe
VENLO, The Netherlands, May 13, 2008 - QIAGEN N.V. today announced that Lynda A. Merrill has joined the Company as Vice-President Molecular Diagnostic Sales for Europe, Middle East, Africa and Australia (EMEAA) on May 1, 2008. In her new role, Lynda will be responsible for sales to QIAGEN's diagnostics customers in the EMEAA-region. She will be based in the U.K. office in Crawley and report to Phillip Sefton, Vice President Commercial Operations EMEAA.
Lynda brings to QIAGEN a wealth of experience in leading roles in the diagnostic industry in the United States and the United Kingdom. In the last 10 years she held leading roles in clinical molecular diagnostics and industrial molecular testing. She joins QIAGEN from Gen-Probe Corporation where she held various positions including Vice-President of World Wide Marketing and Sales and, most recently, as Vice-President for Industrial Relationships. Before joining Gen-Probe, Lynda worked in different management positions in diagnostics at Boehringer Mannheim. She holds a Bachelor of Science and a MBA degree from the University of Sussex, UK.
In her new position at QIAGEN, Lynda will assume leadership of the Company's leading sales force in molecular diagnostics in Europe. Her responsibilities include the sales management of this fast growing business. Currently, the overall size of the European in vitro diagnostics market is estimated to be US$ 9.2 billion. Molecular diagnostics represent approximately 10 percent of this market, yet are one of the fastest growing segments with a global annual compound growth rate of 16 percent. With its broad offering of more sample preparation and assay technologies than any other company in the industry, QIAGEN is a strong leader in this growing market.
"We are extremely pleased to welcome Lynda in our team", said Bernd Uder, QIAGEN's Senior Vice President Global Sales. "As a leading player in the global molecular diagnostics business, QIAGEN is planning a significant expansion of its position in Europe. We are looking forward to building on the immense market opportunities in the EMEAA-region laying ahead of us. Lynda has an excellent track of record and adds to our team valuable experience in leading positions in the molecular diagnostics industry."
About QIAGEN:QIAGEN N.V., a Netherlands holding company, is the leading global provider of sample and assay technologies. Sample technologies are used to isolate and process DNA, RNA and proteins from biological samples such as blood or tissue. Assay technologies are used to make such isolated biomolecules visible. QIAGEN has developed and markets more than 500 consumable products as well as automated solutions for such consumables. The company provides its products to molecular diagnostics laboratories, academic researchers, pharmaceutical and biotechnology companies, and applied testing customers for purposes such as forensics, animal or food testing and pharmaceutical process control. QIAGEN's assay technologies include one of the broadest panels of molecular diagnostic tests available worldwide. This panel includes the only FDA-approved test for human papillomavirus (HPV), the primary cause of cervical cancer. QIAGEN employs more than 2,700 people in over 30 locations worldwide. Further information about QIAGEN can be found at a href="http://www.qiagen.com/" mce_href="http://www.qiagen.com/" title="http://www.qiagen.com/">http://www.qiagen.com/.